Company / Capital Expenditures
Barinthus Biotherapeutics plc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$37.0K
FY2025
5-year range
$37.0K / $6.1M
FY2021-FY2025
Trend
-99.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6M to $37,000 over the past 2 years.
Based on SEC 10-K filings.
$37,000 in FY2025 with a 3-year CAGR of -68.2%.
Declined from $6M to $37,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -68.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -68.2%, indicating a declining trend.
- In FY2025, capital expenditures decreased 99.3% year-over-year.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.0K | -99.3% |
| FY2024 | $5.4M | -11.8% |
| FY2023 | $6.1M | +435.6% |
| FY2022 | $1.1M | +291.1% |
| FY2021 | $293.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026